Skip to main content
. Author manuscript; available in PMC: 2016 May 5.
Published in final edited form as: Clin Cancer Res. 2015 Nov 6;22(7):1699–1712. doi: 10.1158/1078-0432.CCR-15-1772

Figure 5.

Figure 5

SUV39H1 overexpression rescues HR repair suppressed by mTOR inhibitors and blocks the synergy between PARP inhibitors and mTOR inhibitors.

A. Myc-DDK-SUV39H1 plasmid was transiently transfected into U2OS-DR-GFP cells to induce SUV39H1 overexpression. Six hours after transfection of pCBASceI plasmid, mTOR inhibitor EVE (10 μM) or KU (10 μM) was added. The HR repair assay was performed after 48 hours. (Upper panel) Each value is relative to the percentage of GFP-positive cells in pCBASceI-transfected control cells. Results are shown as means±SD from three independent experiments. Lower panel shows the overexpression of SUV39H1 proteins (Myc-Tag mAb) in U2OS-DR-GFP cells. B–C. Myc-DDK-SUV39H1 plasmid was transiently transfected into MDA-MB-231 (B) or BT-549 (C) cells for SUV39H1 overexpression. BMN 673 (BMN) or combinations of BMN and mTOR inhibitors (EVE or KU) were added the next day, and cell proliferation was evaluated with PrestoBlue Cell Viability Reagent 72 hours later. Western blots to demonstrate overexpression of SUV39H1 (Myc-Tag mAb) are at the bottom of each panel.